Athena Bioscience's Qdolo (tramadol hydrochloride) Receives US FDA's NDA Approval for Oral Solution
Shots:
- Athena Biosciences announced that the US FDA has approved Qdolo (tramadol hydrochloride) oral solution 5mg/1mL C-IV
- The most common AE’s (≥15.0%) observed in patients were dizziness/vertigo- nausea- constipation- headache- somnolence- vomiting- and pruritus
- Qdolo is indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. It will be available at chain- independent- and specialty pharmacies
| Ref: PRNewswire | Image: Pharma Compass
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com